Oryzon Genomics SA (ORY) - Net Assets

Latest as of December 2025: €117.85 Million EUR ≈ $137.78 Million USD

Based on the latest financial reports, Oryzon Genomics SA (ORY) has net assets worth €117.85 Million EUR (≈ $137.78 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€144.52 Million ≈ $168.96 Million USD) and total liabilities (€26.68 Million ≈ $31.19 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Oryzon Genomics SA (ORY) strategic asset index to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric Value
Current Net Assets €117.85 Million
% of Total Assets 81.54%
Annual Growth Rate 14.95%
5-Year Change 65.37%
10-Year Change 418.5%
Growth Volatility 33.98

Oryzon Genomics SA - Net Assets Trend (2011–2025)

This chart illustrates how Oryzon Genomics SA's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Oryzon Genomics SA stock valuation.

Annual Net Assets for Oryzon Genomics SA (2011–2025)

The table below shows the annual net assets of Oryzon Genomics SA from 2011 to 2025. Also explore net asset growth rate of Oryzon Genomics SA to track the company's year-over-year net asset growth rate.

Year Net Assets Change
2025-12-31 €117.85 Million
≈ $137.78 Million		 +35.39%
2024-12-31 €87.04 Million
≈ $101.76 Million		 +6.44%
2023-12-31 €81.77 Million
≈ $95.60 Million		 +12.68%
2022-12-31 €72.57 Million
≈ $84.84 Million		 +1.84%
2021-12-31 €71.26 Million
≈ $83.31 Million		 -6.15%
2020-12-31 €75.93 Million
≈ $88.77 Million		 -5.10%
2019-12-31 €80.02 Million
≈ $93.55 Million		 +77.32%
2018-12-31 €45.13 Million
≈ $52.76 Million		 +31.06%
2017-12-31 €34.43 Million
≈ $40.25 Million		 +51.49%
2016-12-31 €22.73 Million
≈ $26.57 Million		 -17.63%
2015-12-31 €27.59 Million
≈ $32.26 Million		 +98.61%
2014-12-31 €13.89 Million
≈ $16.24 Million		 -5.67%
2013-12-31 €14.73 Million
≈ $17.22 Million		 -10.34%
2012-12-31 €16.43 Million
≈ $19.20 Million		 -1.97%
2011-12-31 €16.76 Million
≈ $19.59 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Oryzon Genomics SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 2081215200.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Common Stock €3.99 Million 3.79%
Other Comprehensive Income €-4.09 Million -3.88%
Other Components €126.35 Million 119.82%
Total Equity €105.45 Million 100.00%

Oryzon Genomics SA Competitors by Market Cap

The table below lists competitors of Oryzon Genomics SA ranked by their market capitalization.

Company Market Cap
VIA Labs Inc
TW:6756
 $215.21 Million
Young Fast Optoelectronics Co Ltd
TW:3622
 $215.26 Million
Global Green Chemicals Public Company Limited
BK:GGC
 $215.37 Million
Smart Sand Inc
NASDAQ:SND
 $215.39 Million
Favite Inc
TW:3535
 $214.94 Million
Dogus Gayrimenkul Yatirim Ortakligi AS
IS:DGGYO
 $214.90 Million
The Gold Bond Group Ltd
TA:GOLD
 $214.87 Million
BF Utilities Limited
NSE:BFUTILITIE
 $214.86 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Oryzon Genomics SA's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 87,042,434 to 105,448,753, a change of 18,406,319 (21.1%).
  • Net loss of 2,605,469 reduced equity.
  • New share issuances of 28,654,218 increased equity.
  • Other comprehensive income decreased equity by 8,444,446.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income €-2.61 Million -2.47%
Share Issuances €28.65 Million +27.17%
Other Comprehensive Income €-8.44 Million -8.01%
Other Changes €802.02K +0.76%
Total Change €- 21.15%

Book Value vs Market Value Analysis

This analysis compares Oryzon Genomics SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.97x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 4.40x to 1.97x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2013-12-31 €0.63 €2.80 x
2014-12-31 €0.49 €2.80 x
2015-12-31 €1.00 €2.80 x
2016-12-31 €0.82 €2.80 x
2017-12-31 €1.06 €2.80 x
2018-12-31 €1.17 €2.80 x
2019-12-31 €1.16 €2.80 x
2020-12-31 €1.44 €2.80 x
2021-12-31 €1.35 €2.80 x
2022-12-31 €1.29 €2.80 x
2023-12-31 €1.34 €2.80 x
2024-12-31 €1.35 €2.80 x
2025-12-31 €1.42 €2.80 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Oryzon Genomics SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -2.47%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 0.00%
  • • Asset Turnover: 0.00x
  • • Equity Multiplier: 1.37x
  • Recent ROE (-2.47%) is above the historical average (-3.52%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2013 -14.66% -91.48% 0.08x 1.95x €-3.63 Million
2014 47.87% 50.69% 0.50x 1.88x €5.26 Million
2015 -3.60% -23.32% 0.10x 1.48x €-3.75 Million
2016 -23.97% -740.91% 0.01x 2.19x €-7.72 Million
2017 -15.09% -31000.95% 0.00x 1.77x €-8.64 Million
2018 -2.61% -17.36% 0.10x 1.49x €-5.69 Million
2019 -6.03% -35.85% 0.13x 1.31x €-9.80 Million
2020 -4.48% -35.71% 0.10x 1.24x €-10.99 Million
2021 -6.58% -44.15% 0.11x 1.34x €-11.81 Million
2022 -5.83% -26.95% 0.15x 1.43x €-11.49 Million
2023 -4.10% -23.63% 0.13x 1.31x €-11.53 Million
2024 -4.21% -49.80% 0.07x 1.25x €-12.37 Million
2025 -2.47% 0.00% 0.00x 1.37x €-13.15 Million

Industry Comparison

This section compares Oryzon Genomics SA's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $63,092,318
  • Average return on equity (ROE) among peers: 0.40%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Oryzon Genomics SA (ORY) €117.85 Million -14.66% 0.23x $214.95 Million
Atrys Health SL (ATRY) $75.33 Million -7.37% 1.33x $204.95 Million
Biotechnology Assets S.A. (BST) $6.53 Million 24.09% 1.54x $13.52 Million
Pharma Mar S.A. (PHM) $166.90 Million -21.12% 0.63x $1.51 Billion
Vytrus Biotech S.A. (VYT) $3.61 Million 6.01% 0.72x $135.30 Million

About Oryzon Genomics SA

MC:ORY Spain Biotechnology
Market Cap
$253.38 Million
€216.73 Million EUR
Market Cap Rank
#16391 Global
#107 in Spain
Share Price
€2.80
Change (1 day)
+0.72%
52-Week Range
€2.68 - €3.82
All Time High
€5.14
Categories
Companies in Spain Biotechnology
About

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-… Read more